Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, Grogan TM, Teruya-Feldstein J, Rimsza LM. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood. 2012;119:1459-1467. [PMID: 22167754 DOI: 10.1182/blood-2011-07-363820] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open

For:	Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, Grogan TM, Teruya-Feldstein J, Rimsza LM. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood. 2012;119:1459-1467. [PMID: 22167754 DOI: 10.1182/blood-2011-07-363820] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open

Number

Cited by Other Article(s)

Sarwar S, Tome ME, Billheimer D, Spier C, Smith CL, Persky D, Schmelz M. Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression. Histol Histopathol 2024;39:319-331. [PMID: 37377225 DOI: 10.14670/hh-18-644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2023]

Kang JB, Shen AZ, Gurajala S, Nathan A, Rumker L, Aguiar VRC, Valencia C, Lagattuta KA, Zhang F, Jonsson AH, Yazar S, Alquicira-Hernandez J, Khalili H, Ananthakrishnan AN, Jagadeesh K, Dey K, Daly MJ, Xavier RJ, Donlin LT, Anolik JH, Powell JE, Rao DA, Brenner MB, Gutierrez-Arcelus M, Luo Y, Sakaue S, Raychaudhuri S. Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution. Nat Genet 2023;55:2255-2268. [PMID: 38036787 PMCID: PMC10787945 DOI: 10.1038/s41588-023-01586-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Accepted: 10/19/2023] [Indexed: 12/02/2023]

Affiliation(s)

Joyce B Kang Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Amber Z Shen Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Saisriram Gurajala Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Aparna Nathan Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Laurie Rumker Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Vitor R C Aguiar Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
Cristian Valencia Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Kaitlyn A Lagattuta Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Fan Zhang Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Division of Rheumatology and the Center for Health Artificial Intelligence, University of Colorado School of Medicine, Aurora, CO, USA
Anna Helena Jonsson Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Seyhan Yazar Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Jose Alquicira-Hernandez Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Hamed Khalili Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Ashwin N Ananthakrishnan Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Karthik Jagadeesh Harvard T. H. Chan School of Public Health, Boston, MA, USA
Kushal Dey Harvard T. H. Chan School of Public Health, Boston, MA, USA Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA Physiology, Biophysics and Systems Biology Program, Weill Cornell Medicine, New York, NY, USA
Mark J Daly Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
Ramnik J Xavier Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Laura T Donlin Hospital for Special Surgery, New York, NY, USA Weill Cornell Medicine, New York, NY, USA
Jennifer H Anolik Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Joseph E Powell Garvan Institute of Medical Research, Sydney, New South Wales, Australia
Deepak A Rao Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Michael B Brenner Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Maria Gutierrez-Arcelus Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
Yang Luo Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
Saori Sakaue Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Soumya Raychaudhuri Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA. Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Collapse

Yang R, Deng F, Yang Y, Tian Q, Huangfu S, Yang L, Hou J, Yang G, Pang W, Lu J, Liu H, Chen Y, Gao J, Zhang L. Blue light promotes vitamin C-mediated ferroptosis of melanoma through specifically upregulating transporter SVCT2 and generating Fe². Biomaterials 2023;299:122186. [PMID: 37276798 DOI: 10.1016/j.biomaterials.2023.122186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 05/30/2023] [Accepted: 05/31/2023] [Indexed: 06/07/2023]

Ramonell RP, Brown M, Woodruff MC, Levy JM, Wise SK, DelGaudio J, Duan M, Saney CL, Kyu S, Cashman KS, Hom JR, Fucile CF, Rosenberg AF, Tipton CM, Sanz I, Gibson GC, Lee FEH. Single-cell analysis of human nasal mucosal IgE antibody secreting cells reveals a newly minted phenotype. Mucosal Immunol 2023;16:287-301. [PMID: 36931600 DOI: 10.1016/j.mucimm.2023.02.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 12/27/2022] [Accepted: 02/24/2023] [Indexed: 03/17/2023]

Affiliation(s)

Richard P Ramonell Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Margaret Brown Georgia Institute of Technology, Atlanta, Georgia, USA
Matthew C Woodruff Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA; Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA
Joshua M Levy Department of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA
Sarah K Wise Department of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA
John DelGaudio Department of Otolaryngology - Head and Neck Surgery, Emory University, Atlanta, Georgia, USA
Meixue Duan Georgia Institute of Technology, Atlanta, Georgia, USA
Celia L Saney College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
Shuya Kyu Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, Georgia, USA
Kevin S Cashman Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA; Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA
Jennifer R Hom Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA; Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA
Christopher F Fucile Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA; Informatics Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA
Alexander F Rosenberg Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA; Informatics Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA
Christopher M Tipton Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA; Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA
Ignacio Sanz Emory Autoimmunity Center of Excellence, Emory University, Atlanta, Georgia, USA; Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, Georgia, USA
Gregory C Gibson Georgia Institute of Technology, Atlanta, Georgia, USA
F Eun-Hyung Lee Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, Georgia, USA.

Collapse

Kang JB, Shen AZ, Sakaue S, Luo Y, Gurajala S, Nathan A, Rumker L, Aguiar VRC, Valencia C, Lagattuta K, Zhang F, Jonsson AH, Yazar S, Alquicira-Hernandez J, Khalili H, Ananthakrishnan AN, Jagadeesh K, Dey K, Daly MJ, Xavier RJ, Donlin LT, Anolik JH, Powell JE, Rao DA, Brenner MB, Gutierrez-Arcelus M, Raychaudhuri S. Mapping the dynamic genetic regulatory architecture of HLA genes at single-cell resolution. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2023:2023.03.14.23287257. [PMID: 36993194 PMCID: PMC10055604 DOI: 10.1101/2023.03.14.23287257] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 06/19/2023]

Affiliation(s)

Joyce B. Kang Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Amber Z. Shen Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Saori Sakaue Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Yang Luo Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
Saisriram Gurajala Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Aparna Nathan Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Laurie Rumker Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Vitor R. C. Aguiar Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
Cristian Valencia Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Kaitlyn Lagattuta Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Fan Zhang Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Division of Rheumatology and the Center for Health Artificial Intelligence, University of Colorado School of Medicine, Aurora, CO, USA
Anna Helena Jonsson Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Seyhan Yazar Garvan Institute of Medical Research, Sydney, NSW, Australia
Jose Alquicira-Hernandez Garvan Institute of Medical Research, Sydney, NSW, Australia
Hamed Khalili Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Ashwin N. Ananthakrishnan Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Karthik Jagadeesh Harvard T. H. Chan School of Public Health, Boston, MA, USA
Kushal Dey Harvard T. H. Chan School of Public Health, Boston, MA, USA
Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network
Mark J. Daly Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital, Boston, MA, USA The Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
Ramnik J. Xavier Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Laura T. Donlin Hospital for Special Surgery, New York, NY, USA Weill Cornell Medicine, New York, NY, USA
Jennifer H. Anolik Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA
Joseph E. Powell Garvan Institute of Medical Research, Sydney, NSW, Australia
Deepak A. Rao Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Michael B. Brenner Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
Maria Gutierrez-Arcelus Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
Soumya Raychaudhuri Center for Data Sciences, Brigham and Women’s Hospital, Boston, MA, USA Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA

Collapse

Takahara T, Nakamura S, Tsuzuki T, Satou A. The Immunology of DLBCL. Cancers (Basel) 2023;15:cancers15030835. [PMID: 36765793 PMCID: PMC9913124 DOI: 10.3390/cancers15030835] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 01/23/2023] [Accepted: 01/25/2023] [Indexed: 01/31/2023] Open

Song S, Deng X, Jiang S, Tian C, Han J, Chai J, Li N, Yan Y, Luo Z. GRAP2 is a prognostic biomarker and correlated with immune infiltration in lung adenocarcinoma. J Clin Lab Anal 2022;36:e24662. [PMID: 36181310 DOI: 10.1002/jcla.24662] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 07/22/2022] [Accepted: 08/02/2022] [Indexed: 11/06/2022] Open

Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Role of B cells as antigen presenting cells. Front Immunol 2022;13:954936. [PMID: 36159874 PMCID: PMC9493130 DOI: 10.3389/fimmu.2022.954936] [Citation(s) in RCA: 52] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 08/19/2022] [Indexed: 01/27/2023] Open

Chen W, Liang W, He Y, Liu C, Chen H, Lv P, Yao Y, Zhou H. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma. Med Oncol 2022;39:44. [PMID: 35092504 DOI: 10.1007/s12032-021-01642-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Accepted: 12/23/2021] [Indexed: 01/01/2023]

Perincheri S. Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies. Front Oncol 2021;11:719140. [PMID: 34956859 PMCID: PMC8692247 DOI: 10.3389/fonc.2021.719140] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 11/16/2021] [Indexed: 12/20/2022] Open

HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients. Cancers (Basel) 2021;13:cancers13225833. [PMID: 34830986 PMCID: PMC8616181 DOI: 10.3390/cancers13225833] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 11/10/2021] [Accepted: 11/17/2021] [Indexed: 11/25/2022] Open

Abstract

Simple Summary

Classic Hodgkin lymphoma (cHL) is a B-cell malignancy with involvement of Epstein–Barr virus (EBV) in about 30% of the European population. The risk to develop cHL is strongly linked to genetic variants in the human leukocyte antigen (HLA) genomic region and to certain HLA alleles. This may be caused by the function of HLA alleles, or by genetic linkage to non-HLA genes. HLA can present EBV-derived and tumour-cell specific antigens and this may lead to anti-tumour immune responses. However, the tumour cells downregulate HLA expression in a proportion of the cases, which may result in immune escape. In this study, we tested whether the loss of HLA expression is related to the presence of certain protective HLA alleles. We found that loss and retention of HLA expression is indeed associated with presence of known susceptibility HLA alleles. These findings suggest that HLA itself is involved in development of cHL.

Abstract

Several human leukocyte antigen (HLA) alleles are strongly associated with susceptibility to classic Hodgkin lymphoma (cHL), also in subgroups stratified for presence of the Epstein–Barr virus (EBV). We tested the hypothesis that the pressure on cHL tumour cells to lose HLA expression is associated with HLA susceptibility alleles. A meta-analysis was carried out to identify consistent protective and risk HLA alleles in a combined cohort of 839 cHL patients from the Netherlands and the United Kingdom. Tumour cell HLA expression was studied in 338 cHL cases from these two cohorts and correlated to the presence of specific susceptibility HLA alleles. Carriers of the HLA-DRB1*07 protective allele frequently lost HLA class II expression in cHL overall. Patients carrying the HLA-DRB1*15/16 (DR2) risk allele retained HLA class II expression in EBV− cHL and patients with the HLA-B*37 risk allele retained HLA class I expression more frequently than non-carriers in EBV+ cHL. The other susceptibility alleles showed no significant differences in expression. Thus, HLA expression by tumour cells is associated with a subset of the protective and risk alleles. This strongly suggests that HLA associations in cHL are related to peptide binding capacities of specific HLA alleles.

Collapse

Ennishi D. The biology of the tumor microenvironment in DLBCL: Targeting the "don't eat me" signal. J Clin Exp Hematop 2021;61:210-215. [PMID: 34511583 PMCID: PMC8808113 DOI: 10.3960/jslrt.21015] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open

Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade. Blood Adv 2021;5:1816-1829. [PMID: 33787861 DOI: 10.1182/bloodadvances.2020003080] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Accepted: 02/16/2021] [Indexed: 12/22/2022] Open

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements. Cancers (Basel) 2021;13:cancers13040887. [PMID: 33672644 PMCID: PMC7924187 DOI: 10.3390/cancers13040887] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 02/12/2021] [Accepted: 02/15/2021] [Indexed: 01/07/2023] Open

Abstract

Simple Summary

The current version of the World-Health-Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues acknowledges the provisional entity of high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH) which is associated with dire prognosis compared to triple-negative diffuse-large-B-cell-lymphoma (tnDLBCL). There is growing evidence for the essential prognostic role of the tumor-microenvironment (TME) and especially the extent of tumor-infiltration by the adaptive immune-system through tumor-infiltrating-lymphocytes (TIL) across a variety of cancers. More precisely, the clonal-architecture of the tumor-infiltrating T-cell-receptor (TCR)-repertoire has recently emerged as a key determinant of risk-stratification in patients with hematological malignancies. Moreover, inflammation-based prognostic-scores, such as the Glasgow-prognostic-score (GPS) were shown to reflect the TME. We therefore performed a large scale next-generation-sequencing (NGS) and clinicopathological study of the TCR-β-chain-repertoire in HGBL-DH/TH revealing several entity-exclusive clonotypes distinct from tnDLBCL, suggestive of tumor-neoantigen-selection and correlate our findings with the GPS in context of clinical outcome in HGBL-DH/TH.

Abstract

High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements (double/triple-hit high grade B-cell lymphoma, HGBL-DH/TH) constitutes a provisional entity among B-cell malignancies with an aggressive behavior and dire prognosis. While evidence for the essential prognostic role of the composition of the tumor-microenvironment (TME) in hematologic malignancies is growing, its prognostic impact in HGBL-DH/TH remains unknown. In this study, we outline the adaptive immune response in a cohort of 47 HGBL-DH/TH and 27 triple-negative diffuse large B-cell lymphoma (tnDLBCL) patients in a large-scale, next-generation sequencing (NGS) investigation of the T-cell receptor (TCR) β-chain repertoire and supplement our findings with data on the Glasgow-Prognostic Score (GPS) at diagnosis, as a score-derived measure of systemic inflammation. We supplement these studies with an immunophenotypic investigation of the TME. Our findings demonstrate that the clonal architecture of the TCR repertoire of HGBL-DH/TH differs significantly from tnDLBCL. Moreover, several entity-exclusive clonotypes, suggestive of tumor-neoantigen selection are identified. Additionally, both productive clonality and percentage of maximum frequency clone as measures of TCR repertoire diversity and tumor-directed activity of the adaptive immune system had significant impact on overall survival (OS; productive clonality: p = 0.0273; HR: 2.839; CI: 1.124–7.169; maximum productive frequency: p = 0.0307; HR: 2.167; CI: 1.074–4.370) but not PFS (productive clonality: p = 0.4459; maximum productive frequency: p = 0.5567) in HGBL-DH/TH patients, while GPS was a significant predictor of both OS and PFS (OS: p < 0.0001; PFS: p = 0.0002). Subsequent multivariate analysis revealed GPS and the revised international prognostic index (R-IPI) to be the only prognosticators holding significant impact for OS (GPS: p = 0.038; R-IPI: p = 0.006) and PFS (GPS: p = 0.029; R-IPI: p = 0.006) in HGBL-DH/TH. Through the identification of expanded, recurrent and entity-exclusive TCR-clonotypes we provide indications for a distinct subset of tumor-neoantigenic elements exclusively shared among HGBL-DH/TH. Further, we demonstrate an adverse prognostic role for both systemic inflammation and uniform adaptive immune response.

Collapse

Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a New Molecular Taxonomy of Diffuse Large B-cell Lymphoma. Cancer Discov 2020;10:1267-1281. [DOI: 10.1158/2159-8290.cd-20-0174] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Revised: 05/04/2020] [Accepted: 05/07/2020] [Indexed: 11/16/2022]

Felce SL, Anderson AP, Maguire S, Gascoyne DM, Armstrong RN, Wong KK, Li D, Banham AH. CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model. Front Oncol 2020;10:448. [PMID: 32309216 PMCID: PMC7145990 DOI: 10.3389/fonc.2020.00448] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 03/13/2020] [Indexed: 11/13/2022] Open

Abstract

The interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease that remains incurable in ~40% of patients treated with R-CHOP immunochemotherapy. The FOXP1 transcription factor is abundantly expressed in such high-risk DLBCL and we recently identified its regulation of immune response signatures, in particular, its suppression of the cell surface expression of major histocompatibility class II (MHC-II), which has a critical role in antigen presentation to T cells. Using CRISPR/Cas9 genome editing we have depleted Foxp1 expression in the aggressive murine A20 lymphoma cell line. When grown in BALB/c mice, this cell line provides a high-fidelity immunocompetent disseminated lymphoma model that displays many characteristics of human DLBCL. Transient Foxp1-depletion using siRNA, and stable depletion using CRISPR (generated by independently targeting Foxp1 exon six or seven) upregulated cell surface I-Ab (MHC-II) expression without impairing cell viability in vitro. RNA sequencing of Foxp1-depleted A20 clones identified commonly deregulated genes, such as the B-cell marker Cd19, and hallmark DLBCL signatures such as MYC-targets and oxidative phosphorylation. Immunocompetent animals bearing Foxp1-depleted A20 lymphomas showed significantly-improved survival, and 20% did not develop tumors; consistent with modulating immune surveillance, this was not observed in immunodeficient NOD SCIDγ mice. The A20 Foxp1 CRISPR model will help to further characterize the contribution of Foxp1 to lymphoma immune evasion and the potential for Foxp1 targeting to synergize with other immunotherapies.

Collapse

Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, Ammatuna E, Zu Eulenburg C, Nijland M, Huls G, Bremer E, van Meerten T. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Cancer Immunol Res 2019;7:1663-1671. [PMID: 31409608 DOI: 10.1158/2326-6066.cir-18-0781] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2018] [Revised: 02/27/2019] [Accepted: 08/09/2019] [Indexed: 11/16/2022]

Mulder TA, Wahlin BE, Österborg A, Palma M. Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application. Cancers (Basel) 2019;11:cancers11070915. [PMID: 31261914 PMCID: PMC6678966 DOI: 10.3390/cancers11070915] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 06/21/2019] [Accepted: 06/25/2019] [Indexed: 02/08/2023] Open

PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood 2019;133:2401-2412. [PMID: 30975638 DOI: 10.1182/blood.2018889931] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Accepted: 04/04/2019] [Indexed: 12/19/2022] Open

Mlynarczyk C, Fontán L, Melnick A. Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunol Rev 2019;288:214-239. [PMID: 30874354 PMCID: PMC6518944 DOI: 10.1111/imr.12755] [Citation(s) in RCA: 78] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 02/11/2019] [Accepted: 02/11/2019] [Indexed: 02/06/2023]

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C. Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer Discov 2019;9:546-563. [PMID: 30705065 DOI: 10.1158/2159-8290.cd-18-1090] [Citation(s) in RCA: 178] [Impact Index Per Article: 35.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2018] [Revised: 12/21/2018] [Accepted: 01/28/2019] [Indexed: 12/21/2022]

Affiliation(s)

Daisuke Ennishi Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Katsuyoshi Takata Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Wendy Béguelin Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York
Gerben Duns Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Anja Mottok Institute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany
Pedro Farinha Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Ali Bashashati Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada
Saeed Saberi Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada
Merrill Boyle Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Barbara Meissner Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Susana Ben-Neriah Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Bruce W Woolcock Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Adèle Telenius Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Daniel Lai Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada
Matt Teater Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York
Robert Kridel Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Kerry J Savage Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Laurie H Sehn Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Ryan D Morin Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
Marco A Marra Genome Science Centre, British Columbia Cancer, Vancouver, British Columbia, Canada
Sohrab P Shah Molecular Oncology, British Columbia Cancer, Vancouver, British Columbia, Canada
Joseph M Connors Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Randy D Gascoyne Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
David W Scott Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada
Ari M Melnick Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, New York
Christian Steidl Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada.

Collapse

Persky DO, Li H, Rimsza LM, Barr PM, Popplewell LL, Bane CL, Von Gehr A, LeBlanc M, Fisher RI, Smith SM, Friedberg JW. A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 2018;93:486-493. [PMID: 29266344 DOI: 10.1002/ajh.25010] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Revised: 12/07/2017] [Accepted: 12/17/2017] [Indexed: 02/06/2023]

van der Meeren LE, Visser L, Diepstra A, Nijland M, van den Berg A, Kluin PM. Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma. Histopathology 2018;72:886-888. [DOI: 10.1111/his.13445] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]

Wong KK, Gascoyne DM, Soilleux EJ, Lyne L, Spearman H, Roncador G, Pedersen LM, Møller MB, Green TM, Banham AH. FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures. Oncotarget 2018;7:52940-52956. [PMID: 27224915 PMCID: PMC5288160 DOI: 10.18632/oncotarget.9507] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2016] [Accepted: 05/04/2016] [Indexed: 01/24/2023] Open

Abstract

FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell malignancy multiple myeloma but has not been studied in DLBCL, where a poor prognosis activated B-cell (ABC)-like subtype display partially blocked plasma cell differentiation. FOXP2 protein expression was detected in ABC-DLBCL cell lines, and in primary DLBCL samples tumoral FOXP2 protein expression was detected in both germinal center B-cell-like (GCB) and non-GCB DLBCL. In biopsies from DLBCL patients treated with immunochemotherapy (R-CHOP), ≥ 20% nuclear tumoral FOXP2-positivity (n = 24/158) correlated with significantly inferior overall survival (OS: P = 0.0017) and progression-free survival (PFS: P = 0.0096). This remained significant in multivariate analysis against either the international prognostic index score or the non-GCB DLBCL phenotype (P < 0.05 for both OS and PFS). Expression of BLIMP1, a marker of plasmacytic differentiation that is commonly inactivated in ABC-DLBCL, did not correlate with patient outcome or FOXP2 expression in this series. Increased frequency of FOXP2 expression significantly correlated with FOXP1-positivity (P = 0.0187), and FOXP1 co-immunoprecipitated FOXP2 from ABC-DLBCL cells indicating that these proteins can co-localize in a multi-protein complex. FOXP2-positive DLBCL had reduced expression of HIP1R (P = 0.0348), which is directly repressed by FOXP1, and exhibited distinct patterns of gene expression. Specifically in ABC-DLBCL these were associated with lower expression of immune response and T-cell receptor signaling pathways. Further studies are warranted to investigate the potential functional cooperativity between FOXP1 and FOXP2 in repressing immune responses during the pathogenesis of high-risk DLBCL.

Collapse

Hilmenyuk T, Ruckstuhl CA, Hayoz M, Berchtold C, Nuoffer JM, Solanki S, Keun HC, Beavis PA, Riether C, Ochsenbein AF. T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma. Oncoimmunology 2018;7:e1365997. [PMID: 29296517 DOI: 10.1080/2162402x.2017.1365997] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Revised: 07/16/2017] [Accepted: 08/05/2017] [Indexed: 12/30/2022] Open

Deravi N, Berke O, Woods JP, Bienzle D. Specific immunotypes of canine T cell lymphoma are associated with different outcomes. Vet Immunol Immunopathol 2017;191:5-13. [PMID: 28895866 DOI: 10.1016/j.vetimm.2017.07.008] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2017] [Revised: 07/17/2017] [Accepted: 07/18/2017] [Indexed: 11/30/2022]

Nijland M, Veenstra RN, Visser L, Xu C, Kushekhar K, van Imhoff GW, Kluin PM, van den Berg A, Diepstra A. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy? Oncoimmunology 2017;6:e1295202. [PMID: 28507804 PMCID: PMC5414870 DOI: 10.1080/2162402x.2017.1295202] [Citation(s) in RCA: 74] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 01/31/2017] [Accepted: 02/08/2017] [Indexed: 02/09/2023] Open

García-Álvarez M, Alcoceba M, López-Parra M, Puig N, Antón A, Balanzategui A, Prieto-Conde I, Jiménez C, Sarasquete ME, Chillón MC, Gutiérrez ML, Corral R, Alonso JM, Queizán JA, Vidán J, Pardal E, Peñarrubia MJ, Bastida JM, García-Sanz R, Marín L, González M. HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis. PLoS One 2017;12:e0172978. [PMID: 28249016 PMCID: PMC5332061 DOI: 10.1371/journal.pone.0172978] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Accepted: 02/12/2017] [Indexed: 12/18/2022] Open

Affiliation(s)

María García-Álvarez Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Miguel Alcoceba Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain CIBERONC, Madrid, Spain
Miriam López-Parra Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Noemí Puig Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Alicia Antón Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Ana Balanzategui Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Isabel Prieto-Conde Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Cristina Jiménez Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
María E. Sarasquete Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
M. Carmen Chillón Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain CIBERONC, Madrid, Spain
María Laura Gutiérrez Cytometry Service-NUCLEUS, Department of Medicine, Cancer Research Center (IBMCC-CSIC/USAL) and IBSAL (University of Salamanca), Salamanca, Spain
Rocío Corral Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
José María Alonso Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain
José Antonio Queizán Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain
Julia Vidán Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain
Emilia Pardal Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain
María Jesús Peñarrubia Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain
José M. Bastida Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain
Ramón García-Sanz Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain * E-mail:
Luis Marín Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain CIBERONC, Madrid, Spain
Marcos González Department of Hematology, University Hospital of Salamanca (HUS-IBSAL), Salamanca, Spain Cooperative Working Group on Lymphomas and Lymphoproliferative Disorders of the Castilla y León Society of Hematology and Hemotherapy (SCLHH), Castilla y León, Spain CIBERONC, Madrid, Spain

Collapse

Gascoyne DM, Lyne L, Spearman H, Buffa FM, Soilleux EJ, Banham AH. Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D. Endocrinology 2017;158:503-515. [PMID: 28001444 PMCID: PMC5460784 DOI: 10.1210/en.2016-1802] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Accepted: 12/19/2016] [Indexed: 12/16/2022]

Kendrick S, Rimsza LM, Scott DW, Slack GW, Farinha P, Tan KL, Persky D, Puvvada S, Connors JM, Sehn L, Gascoyne RD, Schmelz M. Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma. Virchows Arch 2016;470:113-117. [PMID: 27888357 DOI: 10.1007/s00428-016-2041-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2016] [Revised: 10/11/2016] [Accepted: 11/07/2016] [Indexed: 01/06/2023]

Tada K, Maeshima AM, Hiraoka N, Yamauchi N, Maruyama D, Kim SW, Watanabe T, Katayama N, Heike Y, Tobinai K, Kobayashi Y. Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy. Cancer Immunol Immunother 2016;65:1213-22. [PMID: 27522583 PMCID: PMC11029644 DOI: 10.1007/s00262-016-1883-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 08/06/2016] [Indexed: 12/17/2022]

Affiliation(s)

Kohei Tada Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan Immunotherapy and Cell Therapy Service, St. Luke's International Hospital, Tokyo, Japan
Akiko Miyagi Maeshima Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
Nobuyoshi Hiraoka Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan
Nobuhiko Yamauchi Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Dai Maruyama Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Sung-Won Kim Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Takashi Watanabe Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan
Naoyuki Katayama Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
Yuji Heike Immunotherapy and Cell Therapy Service, St. Luke's International Hospital, Tokyo, Japan Immunotherapy Research Field, Translational Research Group, and Translational Medicine Department, Phase 1 Group, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan
Kensei Tobinai Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
Yukio Kobayashi Department of Hematology and Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

Collapse

Puvvada S, Li H, Rimsza LM, Bernstein SH, Fisher RI, LeBlanc M, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 2016;57:2359-69. [PMID: 26758422 PMCID: PMC5140034 DOI: 10.3109/10428194.2015.1135431] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]

Gascoyne DM, Banham AH. The significance of FOXP1 in diffuse large B-cell lymphoma. Leuk Lymphoma 2016;58:1037-1051. [PMID: 27678023 DOI: 10.1080/10428194.2016.1228932] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2016;1863:471-482. [DOI: 10.1016/j.bbamcr.2015.11.003] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Revised: 10/27/2015] [Accepted: 11/04/2015] [Indexed: 12/29/2022]

HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma. Arch Immunol Ther Exp (Warsz) 2015;64:225-40. [PMID: 26667793 DOI: 10.1007/s00005-015-0372-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2015] [Accepted: 09/14/2015] [Indexed: 02/01/2023]

Brown PJ, Wong KK, Felce SL, Lyne L, Spearman H, Soilleux EJ, Pedersen LM, Møller MB, Green TM, Gascoyne DM, Banham AH. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. Leukemia 2015;30:605-16. [PMID: 26500140 PMCID: PMC4777777 DOI: 10.1038/leu.2015.299] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2015] [Revised: 10/07/2015] [Accepted: 10/13/2015] [Indexed: 12/25/2022]

Testoni M, Zucca E, Young KH, Bertoni F. Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol 2015;26:1069-1080. [PMID: 25605746 PMCID: PMC4542576 DOI: 10.1093/annonc/mdv019] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2014] [Revised: 12/05/2014] [Accepted: 12/15/2014] [Indexed: 01/04/2023] Open

Upadhyay R, Hammerich L, Peng P, Brown B, Merad M, Brody JD. Lymphoma: immune evasion strategies. Cancers (Basel) 2015;7:736-62. [PMID: 25941795 PMCID: PMC4491682 DOI: 10.3390/cancers7020736] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Revised: 04/21/2015] [Accepted: 04/23/2015] [Indexed: 01/21/2023] Open

Luria L, Nguyen J, Zhou J, Jaglal M, Sokol L, Messina JL, Coppola D, Zhang L. Manifestations of gastrointestinal plasmablastic lymphoma: A case series with literature review. World J Gastroenterol 2014;20:11894-11903. [PMID: 25206297 PMCID: PMC4155383 DOI: 10.3748/wjg.v20.i33.11894] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2014] [Revised: 03/22/2014] [Accepted: 05/26/2014] [Indexed: 02/06/2023] Open

Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer 2014;14:517-34. [PMID: 25008267 DOI: 10.1038/nrc3774] [Citation(s) in RCA: 373] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]

Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, Watanabe R, Takasaki H, Motomura S, Kobayashi S, Yokose T, Ishigatsubo Y, Sakai R. Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. Leuk Lymphoma 2014;55:2721-7. [PMID: 24528218 DOI: 10.3109/10428194.2014.893311] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]

Cycon KA, Mulvaney K, Rimsza LM, Persky D, Murphy SP. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology 2013;140:259-72. [PMID: 23789844 DOI: 10.1111/imm.12136] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Revised: 06/11/2013] [Accepted: 06/13/2013] [Indexed: 12/29/2022] Open

HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. Blood 2013;122:1448-54. [PMID: 23843497 DOI: 10.1182/blood-2013-02-483420] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open

Schmelz M, Montes-Moreno S, Piris M, Wilkinson ST, Rimsza LM. Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica 2012;97:1614-6. [PMID: 22689685 DOI: 10.3324/haematol.2011.060186] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open